Dorsey & Whitney Trust CO LLC Trims Position in CVS Health Co. (NYSE:CVS)

Dorsey & Whitney Trust CO LLC lessened its stake in shares of CVS Health Co. (NYSE:CVS) by 43.8% in the fourth quarter, Holdings Channel reports. The institutional investor owned 6,663 shares of the pharmacy operator’s stock after selling 5,195 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in CVS Health were worth $299,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. TD Private Client Wealth LLC grew its holdings in CVS Health by 28.7% during the 3rd quarter. TD Private Client Wealth LLC now owns 46,938 shares of the pharmacy operator’s stock valued at $2,951,000 after buying an additional 10,465 shares in the last quarter. Principal Financial Group Inc. grew its holdings in shares of CVS Health by 4.8% during the third quarter. Principal Financial Group Inc. now owns 1,434,476 shares of the pharmacy operator’s stock worth $90,200,000 after purchasing an additional 66,244 shares in the last quarter. Sompo Asset Management Co. Ltd. grew its holdings in shares of CVS Health by 8.4% during the third quarter. Sompo Asset Management Co. Ltd. now owns 134,523 shares of the pharmacy operator’s stock worth $8,459,000 after purchasing an additional 10,453 shares in the last quarter. Hall Laurie J Trustee grew its holdings in shares of CVS Health by 25,484.4% during the fourth quarter. Hall Laurie J Trustee now owns 11,513 shares of the pharmacy operator’s stock worth $517,000 after purchasing an additional 11,468 shares in the last quarter. Finally, B&D White Capital Company LLC purchased a new position in shares of CVS Health during the fourth quarter worth about $417,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insider Transactions at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the sale, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at $556,941.90. This represents a 47.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Michael F. Mahoney acquired 30,000 shares of the stock in a transaction on Tuesday, February 18th. The shares were purchased at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the transaction, the director now directly owns 39,356 shares of the company’s stock, valued at approximately $2,625,045.20. This trade represents a 320.65 % increase in their position. The disclosure for this purchase can be found here. Corporate insiders own 0.24% of the company’s stock.

Analyst Ratings Changes

CVS has been the subject of several recent analyst reports. Argus set a $77.00 price objective on CVS Health in a report on Tuesday, February 18th. Barclays boosted their price objective on CVS Health from $71.00 to $73.00 and gave the stock an “overweight” rating in a report on Thursday, February 13th. Leerink Partners raised CVS Health from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $55.00 to $75.00 in a report on Thursday, February 13th. Evercore ISI boosted their target price on CVS Health from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Monday, January 27th. Finally, Royal Bank of Canada dropped their target price on CVS Health from $68.00 to $58.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Four analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $69.83.

CVS Health Trading Down 1.8 %

NYSE CVS opened at $65.13 on Tuesday. The stock has a market cap of $82.11 billion, a P/E ratio of 17.79, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. CVS Health Co. has a fifty-two week low of $43.56 and a fifty-two week high of $80.75. The stock has a 50 day simple moving average of $56.84 and a two-hundred day simple moving average of $56.78. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, beating the consensus estimate of $0.89 by $0.30. CVS Health had a net margin of 1.24% and a return on equity of 9.11%. On average, analysts forecast that CVS Health Co. will post 5.89 earnings per share for the current year.

CVS Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Shareholders of record on Thursday, January 23rd were given a dividend of $0.665 per share. The ex-dividend date of this dividend was Thursday, January 23rd. This represents a $2.66 annualized dividend and a yield of 4.08%. CVS Health’s payout ratio is 72.68%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.